Tumour clonal evolution tracking
Sequencing several parts of a tumour, or blood over time, to draw its family tree of mutations and see which branches drive relapse and resistance.
Overview
Multi-region and longitudinal sequencing reconstruct a tumour's subclonal architecture and phylogeny. Studies such as TRACERx in lung cancer showed that chromosomal instability and subclonal expansion predict relapse, and that circulating tumour DNA can track which clones survive treatment. The concepts of truncal versus branch mutations shape target selection: a drug against a truncal mutation hits every cell, one against a branch mutation hits only a subclone.
How it works
Sequence multiple tumour regions or serial plasma samples, cluster mutations by cellular fraction, and build phylogenetic trees that order events and quantify heterogeneity.
- Explains resistance and relapse mechanistically
- Distinguishes truncal targets from subclonal ones
- Now feasible from blood over time
- Sampling still misses clones
- Analysis methods vary
- Not yet a clinical test
Latest papers
topQuery for this technology: (TITLE:"Tumour clonal evolution tracking" OR ABSTRACT:"Tumour clonal evolution tracking") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tumour clonal evolution tracking, not a curated reading list.
Similar pages
not linked directly; found by shared links- CompanyVolitionRx
- PersonMaximilian Diehn
Shares MRD / molecular residual disease testing, Liquid biopsy (ctDNA), Non-small-cell lung cancer.
- CompanyBiodesix
- PersonNatasha B. Leighl
- CompanyBillionToOne
Shares MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- PersonAsh A. Alizadeh
Shares MRD / molecular residual disease testing, Liquid biopsy (ctDNA), Non-small-cell lung cancer.
- PersonDaniel A. Haber
- PersonSarah-Jane Dawson
Shares MRD / molecular residual disease testing, Liquid biopsy (ctDNA).